PLUS1
4.23
0.11 (2.67%)
0.11 (2.67%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sorrento Therapeutics Inc | SRNE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.26 | 6.74% | 4.12 | 4.00 | 4.56 | 4.20 | 3.86 | 00:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.22 | 4.26 | 0.04 | 0.94% | 1 | 1 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 86,330 | 33,729,243 | $ 4.21 | $ 142,004,973 | 47,598,182 | 1.39 - 10.61 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:47 | formt | 3,750 | $ 4.23 | USD |
Sorrento Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 863.92M | 209.69M | 105.18M | $ 31.43M | $ - | -2.20 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Sorrento Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/05/2020 | 09:32 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/05/2020 | 09:30 | PR Newswire (US) | Sorrento COVIDTRAP™(STI-4398) Demonstrates in Preclinical.. |
| 6/04/2020 | 13:29 | PR Newswire (US) | Moore Kuehn, PLLC Encourages Investors of CLNY, SRNE, and.. |
| 5/26/2020 | 09:00 | GlobeNewswire Inc. | Sorrento Receives FDA IND Clearance to Initiate a Phase I.. |
| 5/21/2020 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/21/2020 | 07:00 | GlobeNewswire Inc. | Sorrento Enters Into Binding Term Sheet to Acquire Exclusive.. |
| 5/15/2020 | 13:53 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRNE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.87 | 5.1213 | 3.82 | 4.44 | 19,211,723 | -0.75 | -15.4% |
| 1 Month | 2.63 | 10.61 | 2.33 | 5.96 | 69,994,269 | 1.49 | 56.65% |
| 3 Months | 2.00 | 10.61 | 1.55 | 5.28 | 27,128,429 | 2.12 | 106.0% |
| 6 Months | 3.63 | 10.61 | 1.55 | 4.90 | 15,702,966 | 0.49 | 13.5% |
| 1 Year | 3.21 | 10.61 | 1.39 | 4.62 | 9,061,477 | 0.91 | 28.35% |
| 3 Years | 1.70 | 10.65 | 1.39 | 4.70 | 4,335,056 | 2.42 | 142.35% |
| 5 Years | 13.97 | 26.80 | 1.39 | 4.92 | 2,771,278 | -9.85 | -70.51% |
Sorrento Therapeutics Description
| Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates. |
